Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02096042 (Clinical Trials/ Brentuximab vedotin)

Study Title
Phase I/II – Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) (NCT02096042)

Trial Description
This clinical research study is made up of 3 phases: a Pilot Phase, Phase I, and Phase II trial.

The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin (also known as SGN-035) to patients with Acute Myeloid Leukemia or AML. The goal of Phase I is to learn more about the safety of the combination of brentuximab vedotin with azacytidine. The goal of Phase II is to learn if the combination of brentuximab vedotin and azacytidine can help to control AML.

This trial is sponsored by Seattle Genetics/ M. D. Anderson Cancer. [1]

Study data

  • Condition: Leukemia
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 61
  • Start: April 2014
  • Estimated Primary Completion: April 2019 (Final data collection date for primary outcome measure
  • Last verified: May 2015

Study Schematic
Screen Shot 2016-07-11 at 11.24.48 AM


Last Editorial review: July 11, 2016

Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar